



SPAFID
CONNECT

Informazione Regolamentata n. 0957-46-2021	Data/Ora Ricezione 23 Luglio 2021 00:36:01	MTA
--	--	-----

Societa' : DiaSorin

Identificativo : 150207

Informazione
Regolamentata

Nome utilizzatore : DIASORINN02 - Fava

Tipologia : 3.1

Data/Ora Ricezione : 23 Luglio 2021 00:36:01

Data/Ora Inizio : 23 Luglio 2021 00:36:02

Diffusione presunta

Oggetto : DiaSorin: Publication of Information
Document under the provisions of the art.
71of the CONSOB Regulation n.
11971/1999

Testo del comunicato

Vedi allegato.



The Diagnostic Specialist

PRESS RELEASE ○○○

DIASORIN: PUBLICATION OF INFORMATION DOCUMENT UNDER THE PROVISIONS OF THE ART. 71 OF THE CONSOB REGULATION N. 11971/1999

Saluggia, July 22, 2021 - DiaSorin (FTSE MIB: DIA) informs that the Information Document issued under the provisions of the art. 71, and in conformity with the Attachment 3B Schedule n. 3, of the CONSOB Regulation n. 11971/1999 and successive amendments, relating to the acquisition of Luminex Corporation, was made available to the public today. Under the provisions of the laws in force, the document is available at the Registered Office, on the company's group website at the following link <https://diasoringroup.com/en/investors/information-shareholders/other-documents>, as well as on the authorized storage eMarket STORAGE mechanism (available at the address www.emarketstorage.com).

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com

Fine Comunicato n.0957-46

Numero di Pagine: 3